May 18, 2015
By Riley McDermid, BioSpace.com Breaking News Sr. Editor
The eyes of the biotech and life sciences world are all fixed on the American Society of Clinical Oncology (ASCO)’s annual meeting in a couple weeks on May 29 through June 2—and BioSpace has got you covered. The world’s biggest cancer research conference, ASCO, puts out about 5,000 datasets known as the “abstract drop,” as it prepares reporters, investors and market participants for what to expect from presenter’s at this year’s gathering. The flood of cancer drug data can sometimes be overwhelming, but BioSpace has handpicked the ones that are likely to be most important—or most disappointing—for the companies looking to take a bite of the multi-billion dollar cancer market in 2015.
2015 ASCO Annual Meeting Abstracts
| Abstract | Session | Type | Time | Location |
| AZN 3014 | Developmental Therapeutics—Immunotherapy | Poster Session | May 30 8AM—11:30AM | S Hall A |
| MRK 3009 | Developmental Therapeutics—Immunotherapy | Poster Session | May 30 8AM—11:30AM | S Hall A |
| AZN 8010 | Immunotherapy in Lung Cancer: A Paradigm Shift | Clinical Science Symposium | May 31 4:30PM—6PM | E Hall D1 |
| BMY 8009 | Immunotherapy in Lung Cancer: A Paradigm Shift | Clinical Science Symposium | May 31 4:30PM—6PM | E Hall D1 |
| MRK 8011 | Immunotherapy in Lung Cancer: A Paradigm Shift | Clinical Science Symposium | May 31 4:30PM—6PM | E Hall D1 |
| PFE 8034 | Lung Cancer—Non-Small Cell Metastatic | Poster Session | June 1 8AM—11:30AM | S Hall A |
| ROCHE 8030 | Lung Cancer—Non-Small Cell Metastatic | Poster Session | June 1 8AM—11:30AM | S Hall A |
| MRK 8026 | Lung Cancer—Non-Small Cell Metastatic | Poster Session | June 1 8AM—11:30AM | S Hall A |
| MRK 8031 | Lung Cancer—Non-Small Cell Metastatic | Poster Session | June 1 8AM—11:30AM | S Hall A |
| MRK 8504 | Lymphoma | Oral Abstract Session | June 1 9:45AM—12:45PM | E450 |
| MRK 4502 | Genitourinary (Nonprostate) Cancer | Oral Abstract Session | June 1 9:45AM—12:45PM | E Arie Crown Theater |
| AZN 3003 | Developmental Therapeutics—Immunotherapy | Oral Abstract Session | June 1 1:15PM—4:15PM | S406 |
| PFE 5509 | Intersection of the Mutanome and the Immunome | Clinical Science Symposium | June 1 3PM—4:30PM | E354b |
| MRK 5510 | Intersection of the Mutanome and the Immunome | Clinical Science Symposium | June 1 3PM—4:30PM | E354b |
| BMY ABBV 8508 | Myeloma | Oral Abstract Session | June 2 9:45AM—12:45PM | E354b |
Will Mylan Buy Teva, As Predator Becomes Prey?
The complicated three-way takeover waltz being conducted between Pittsburgh, Penn.-based Mylan Inc., Israeli company Teva Pharmaceutical Industries Ltd. and Perrigo Company took another weird turn last week, after Mylan said that while it still views Teva’s unsolicited $40.1 billion bid as too low, it might want to acquire Teva itself eventually. Mylan Chairman Robert J. Coury made it clear that if Mylan is able to cement its deal with Perrigo, it might go shopping again—and this time to buy Teva, not be bought. With dealmaking heating up in 2015, we wanted to know your thoughts: Will perennial predator Teva wind up being prey?
